{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:33:43Z","timestamp":1794018823920,"version":"4.8.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>QPX7728 is a novel \u03b2-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam). In this paper we provide the overview of the biochemical, structural and microbiological studies that were recently conducted with QPX7728. We show that QPX7728 is an ultra-broad-spectrum \u03b2-lactamase inhibitor with the broadest spectrum of inhibition reported to date in a single BLI molecule; in addition to potent inhibition of clinically important serine \u03b2-lactamases, including Class A and D carbapenemases from Enterobacterales and notably, diverse Class D carbapenemases from Acinetobacter, it also inhibits many metallo \u03b2-lactamases. Importantly, it is minimally affected by general intrinsic resistance mechanisms such as efflux and porin mutations that impede entry of drugs into gram-negative bacteria. QPX7728 combinations with several intravenous (IV) \u03b2-lactam antibiotics shows broad coverage of Enterobacterales, <jats:italic>Acinetobacter baumannii<\/jats:italic> and <jats:italic>Pseudomonas aeruginosa<\/jats:italic>, including strains that are resistant to other IV \u03b2-lactam-BLI combinations, e.g., ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and imipenem-relebactam that were recently approved for clinical use. Based on studies with <jats:italic>P. aeruginosa<\/jats:italic>, different partner \u03b2-lactams in combination with QPX7728 may be optimal for the coverage of susceptible organisms. This provides microbiological justification for a stand-alone BLI product for co-administration with different \u03b2-lactams. QPX7728 can also be delivered orally; thus, its ultra-broad \u03b2-lactamase inhibition spectrum and other features could be also applied to oral QPX7728-based combination products. Clinical development of QPX7728 has been initiated.<\/jats:p>","DOI":"10.3389\/fmicb.2021.697180","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T08:26:16Z","timestamp":1625473576000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics"],"prefix":"10.3389","volume":"12","author":[{"given":"Olga","family":"Lomovskaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Tsivkovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Totrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Loutit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"e00528","DOI":"10.1128\/mBio.00528-17","article-title":"Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from beta-lactamase protein engineering.","volume":"8","author":"Barnes","year":"2017","journal-title":"MBio"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on beta-lactamases.","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between beta-lactamases and new beta-lactamase inhibitors.","volume":"17","author":"Bush","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00431-016-2763-1","article-title":"Resistance to oral antibiotics in 4569 Gram-negative rods isolated from urinary tract infection in children.","volume":"175","author":"Calzi","year":"2016","journal-title":"Eur. J. Pediatr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1093\/jac\/dkz243","article-title":"Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime\/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.","volume":"74","author":"Castanheira","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B6","year":"2019","journal-title":"Antibiotic Resistance Threats in the United States, 2019."},{"key":"B7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ijantimicag.2018.07.027","article-title":"Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.","volume":"52","author":"Chalhoub","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/femsre\/fux020","article-title":"Structure, function and regulation of Pseudomonas aeruginosa porins.","volume":"41","author":"Chevalier","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"B9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1128\/AAC.01388-10","article-title":"Efflux-mediated antibiotic resistance in Acinetobacter spp.","volume":"55","author":"Coyne","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220265","article-title":"The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017.","volume":"14","author":"Critchley","year":"2019","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.m113.485979","article-title":"Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases.","volume":"288","author":"Ehmann","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2217\/fmb.15.48","article-title":"Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies.","volume":"10","author":"El Zowalaty","year":"2015","journal-title":"Future Microbiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1128\/aac.45.3.660-663.2001","article-title":"Standard numbering scheme for class B beta-lactamases.","volume":"45","author":"Galleni","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"crossref","first-page":"e00573","DOI":"10.1128\/AAC.00573-18","article-title":"Clonal Background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae.","volume":"62","author":"Gomez-Simmonds","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","article-title":"Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged infection.","volume":"4","author":"Hawkey","year":"2018","journal-title":"Microb. Genom."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1021\/acs.jmedchem.1029b01976","article-title":"Discovery of cyclic boronic acid QPX7728, an ultra-broad-spectrum inhibitor of serine and metallo beta-lactamases.","volume":"63","author":"Hecker","year":"2020","journal-title":"J. Med. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs Class A Serine Carbapenemases.","volume":"58","author":"Hecker","year":"2015","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1007\/s11908-019-0690-9","article-title":"Recognizing and overcoming resistance to new beta-lactam\/beta-lactamase inhibitor combinations.","volume":"21","author":"Ho","year":"2019","journal-title":"Curr. Infect. Dis. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of monte carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.","volume":"43","author":"Kuti","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.06.012","article-title":"Comparison of 30-min and 3-h infusion regimens for imipenem\/cilastatin and for meropenem evaluated by Monte Carlo simulation.","volume":"68","author":"Lee","year":"2010","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1128\/cmr.00117-14","article-title":"The challenge of efflux-mediated antibiotic resistance in gram-negative bacteria.","volume":"28","author":"Li","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1128\/aac.42.2.399","article-title":"\u03b2-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa.","volume":"42","author":"Li","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/cmr.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.","volume":"22","author":"Lister","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1128\/aac.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","first-page":"e00552","article-title":"Impact of intrinsic resistance mechanisms on potency of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.","volume":"64","author":"Lomovskaya","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"crossref","first-page":"e00210","DOI":"10.1128\/AAC.00210-21","article-title":"In vitro activity of the ultra-broad-spectrum beta-lactamase inhibitor QPX7728 in combination with multiple beta-lactam antibiotics against Pseudomonas aeruginosa.","volume":"65","author":"Lomovskaya","year":"2021","journal-title":"Antimicrob. Agents Chemother"},{"key":"B27","doi-asserted-by":"crossref","first-page":"e01443","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae.","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","first-page":"e00212","article-title":"Spectrum of beta-lactamase inhibition by the cyclic boronate QPX7728, an ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases: enhancement of activity of multiple antibiotics against isogenic strains expressing single beta-lactamases.","volume":"64","author":"Lomovskaya","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/1120009x.2017.1380395","article-title":"Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.","volume":"29","author":"Mazzariol","year":"2017","journal-title":"J. Chemother."},{"key":"B30","doi-asserted-by":"crossref","first-page":"e00989","DOI":"10.1128\/AAC.00989-17","article-title":"Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity.","volume":"61","author":"Nelson","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","article-title":"QPX7728: resistance selection, prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae","author":"Nelson","year":"2019","journal-title":"Proceedings of the ASM-ESCMID. Abstract #44"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e00757","DOI":"10.1128\/AAC.00757-00720","article-title":"In vitro activity of the ultra-broad-spectrum beta-lactamase inhibitor QPX7728 against carbapenem-resistant enterobacterales (cre) with varying intrinsic and acquired resistance mechanisms.","volume":"64","author":"Nelson","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","first-page":"e01406","article-title":"In vitroactivity of the ultra-broad-spectrum beta-lactamase inhibitor QPX7728 in combination with meropenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii.","volume":"64","author":"Nelson","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1021\/bi992505b","article-title":"Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-Lactamase().","volume":"39","author":"Ness","year":"2000","journal-title":"Biochemistry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1128\/mmbr.67.4.593-656.2003","article-title":"Molecular basis of bacterial outer membrane permeability revisited.","volume":"67","author":"Nikaido","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106179","article-title":"Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients.","volume":"56","author":"Nori","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1128\/jb.181.17.5426-5432.1999","article-title":"Amino acid-mediated induction of the basic amino acid-specific outer membrane porin OprD from Pseudomonas aeruginosa.","volume":"181","author":"Ochs","year":"1999","journal-title":"J. Bacteriol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nrmicro1994","article-title":"The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria.","volume":"6","author":"Pages","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004817","article-title":"Efflux Pump, the masked side of \u00df-Lactam resistance in Klebsiella pneumoniae clinical isolates.","volume":"4","author":"Pages","year":"2009","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","article-title":"The latest advances in beta-lactam\/beta-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.","volume":"20","author":"Papp-Wallace","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"B41","doi-asserted-by":"crossref","first-page":"e00174","DOI":"10.1128\/AAC.00174-18","article-title":"Relebactam is a potent inhibitor of the KPC-2 beta-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae.","volume":"62","author":"Papp-Wallace","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B42","doi-asserted-by":"crossref","first-page":"e00398","DOI":"10.1128\/AAC.00398-20","article-title":"Structural basis and binding kinetics of vaborbactam in class A \u03b2-lactamase inhibition.","volume":"64","author":"Pemberton","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9080635","article-title":"Increased risk of acquisition of New Delhi metallo-beta-lactamase-producing carbapenem-resistant enterobacterales (NDM-CRE) among a cohort of COVID-19 patients in a teaching hospital in tuscany, Italy.","volume":"9","author":"Porretta","year":"2020","journal-title":"Pathogens"},{"key":"B44","author":"Reddy","year":"2014","journal-title":"Boronic Acid Derivatives and Therapeutic Uses Thereof. Patent WO2014107535A1."},{"key":"B45","author":"Reddy","year":"2016","journal-title":"Boronic Acid Derivatives and Therapeutic Uses Thereof. Patent WO2016003929A1."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1128\/aac.02641-15","article-title":"Boronic acid transition state inhibitors active against KPC and other class A beta-lactamases: structure-activity relationships as a guide to inhibitor design.","volume":"60","author":"Rojas","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B47","article-title":"QPX7728: in vitro activity in combination with oral beta-lactam antibiotics against Enterobacteriaceae (ENT)","author":"Rubio-Aparicio","year":"2019","journal-title":"Proceedings of the ASM Microbe AAR-710"},{"key":"B48","doi-asserted-by":"crossref","first-page":"e01267","DOI":"10.1128\/AAC.01267-20","article-title":"In vivo activity of QPX7728, an ultrabroad-spectrum beta-lactamase inhibitor, in combination with beta-lactams against carbapenem-resistant Klebsiella pneumoniae.","volume":"64","author":"Sabet","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.05.005","article-title":"Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).","volume":"96","author":"Sader","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B50","first-page":"e02097","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections.","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1128\/aac.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1099\/mgen.0.000370","article-title":"Antibiotic resistance in Pseudomonas aeruginosa and adaptation to complex dynamic environments.","volume":"6","author":"Sommer","year":"2020","journal-title":"Microbial. Genomics"},{"key":"B53","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/jac\/44.4.537","article-title":"Contribution of the MexAB-OprM multidrug e?ux system to the \u03b2-lactam resistance of penicillin-binding protein and \u03b2-lactamase-derepressed mutants of Pseudomonas aeruginosa.","volume":"44","author":"Srikumar","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciz089","article-title":"The infectious diseases society of America\u2019s 10 x \u201920 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 x \u201820 a Possibility?","volume":"69","author":"Talbot","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1039\/c9md00557a","article-title":"Cyclic boronates as versatile scaffolds for KPC-2 \u03b2-lactamase inhibition.","volume":"11","author":"Tooke","year":"2020","journal-title":"RSC Med. Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cmi.2018.03.038","article-title":"Fluoroquinolones for urinary tract infection and within-household spread of resistant Enterobacteriaceae: the smoking gun.","volume":"24","author":"Trautner","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B57","first-page":"e01935","article-title":"Biochemical activity of vaborbactam.","volume":"64","author":"Tsivkovski","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B58","doi-asserted-by":"crossref","first-page":"e10936","DOI":"10.1128\/AAC.01936-19","article-title":"Potency of vaborbactam is less affected than avibactam in strains producing KPC-2 mutations that confer resistance to ceftazidime-avibactam.","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B59","doi-asserted-by":"crossref","first-page":"e00130","DOI":"10.1128\/AAC.00130-20","article-title":"biochemical characterization of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases.","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jac\/dkl509","article-title":"Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii.","volume":"59","author":"Vila","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"B61","year":"2017","journal-title":"Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics."},{"key":"B62","doi-asserted-by":"crossref","first-page":"e02048","DOI":"10.1128\/AAC.02048-18","article-title":"Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae.","volume":"63","author":"Wilson","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.697180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T08:26:47Z","timestamp":1625473607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.697180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":62,"alternative-id":["10.3389\/fmicb.2021.697180"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.697180","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"article-number":"697180"}}